NASDAQ:AZN - AstraZeneca Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $119.00
  • Forecasted Upside: 104.36 %
  • Number of Analysts: 14
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$58.23
▲ +0.27 (0.47%)

This chart shows the closing price for AZN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AstraZeneca Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AZN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AZN

Analyst Price Target is $119.00
▲ +104.36% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $119.00, with a high forecast of $175.00 and a low forecast of $63.00. The average price target represents a 104.36% upside from the last price of $58.23.

This chart shows the closing price for AZN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 polled investment analysts is to buy stock in AstraZeneca. This rating has held steady since August 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 2 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 2 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 2 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 2 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/21/2021CitigroupReiterated RatingBuyLow
7/16/2021SVB LeerinkLower Price TargetOutperform$64.00 ➝ $63.00Low
6/17/2021UBS GroupReiterated RatingBuyLow
6/4/2021SVB LeerinkBoost Price TargetOutperform$63.00 ➝ $64.00Low
4/19/2021ArgusReiterated RatingBuy ➝ HoldN/A
4/12/2021ArgusDowngradeBuy ➝ HoldMedium
3/23/2021Societe GeneraleReiterated RatingBuyLow
3/18/2021Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
3/16/2021Jefferies Financial GroupUpgradeHold ➝ BuyLow
3/9/2021Berenberg BankReiterated RatingBuyLow
3/8/2021BarclaysReiterated RatingOverweightMedium
3/2/2021SVB LeerinkLower Price TargetOutperform$64.00 ➝ $63.00Low
2/25/2021UBS GroupUpgradeNeutral ➝ BuyMedium
1/22/2021BarclaysReiterated RatingOverweightLow
1/15/2021Berenberg BankReiterated RatingBuyLow
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
12/30/2020AlphaValueUpgradeReduceN/A
12/14/2020UBS GroupReiterated RatingPositiveHigh
12/13/2020Piper SandlerLower Price TargetOverweight$179.00 ➝ $175.00High
12/7/2020Morgan StanleyUpgradeEqual Weight ➝ OverweightLow
11/30/2020UBS GroupUpgradeSell ➝ NeutralMedium
11/23/2020Morgan StanleyReiterated RatingEqual WeightMedium
11/11/2020HSBCUpgradeReduce ➝ HoldLow
9/29/2020Berenberg BankInitiated CoverageBuyLow
9/23/2020Oddo BhfUpgradeReduce ➝ BuyLow
7/29/2020BarclaysReiterated RatingOverweightLow
6/24/2020Oddo BhfDowngradeBuy ➝ ReduceLow
6/10/2020CowenBoost Price Target$55.00 ➝ $60.00Low
6/4/2020UBS GroupReiterated RatingSellLow
5/29/2020GuggenheimReiterated RatingBuyMedium
5/29/2020SVB LeerinkBoost Price TargetOutperform$60.00 ➝ $65.00Low
5/6/2020Morgan StanleyReiterated RatingEqual WeightLow
5/6/2020ArgusBoost Price TargetBuy$54.00 ➝ $60.00Low
5/1/2020GuggenheimReiterated RatingBuyLow
4/27/2020BarclaysReiterated RatingOverweightLow
4/23/2020FIG PartnersInitiated CoverageReduceLow
4/15/2020Morgan StanleyReiterated RatingEqual WeightLow
2/28/2020CowenReiterated RatingBuy$55.00High
12/2/2019CowenReiterated RatingOutperform$48.00 ➝ $55.00Low
11/11/2019CowenReiterated RatingBuy$48.00Low
10/24/2019Liberum CapitalReiterated RatingHold ➝ HoldLow
9/3/2019DZ BankDowngradeHold ➝ SellLow
8/14/2019ArgusBoost Price TargetBuy$50.00Medium
4/29/2019Pareto SecuritiesUpgradeSell ➝ HoldLow
4/2/2019UBS GroupDowngradeNeutral ➝ Sell$40.73Medium
4/1/2019CowenUpgradeMarket Perform ➝ Outperform$42.00 ➝ $48.00Low
3/19/2019Main First BankReiterated RatingBuyLow
2/28/2019HSBCReiterated RatingSellMedium
2/26/2019Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
2/26/2019The Goldman Sachs GroupReiterated RatingSellLow
2/5/2019Exane BNP ParibasInitiated CoverageOutperformLow
2/5/2019BNP ParibasInitiated CoverageOutperform ➝ OutperformLow
1/15/2019BMO Capital MarketsReiterated RatingBuy$48.00Medium
12/14/2018Bank of AmericaReiterated RatingBuyLow
12/13/2018SunTrust BanksInitiated CoverageBuy$48.00Low
12/11/2018Jefferies Financial GroupReiterated RatingHold ➝ Hold$42.00Medium
12/9/2018Credit Suisse GroupReiterated RatingBuyLow
11/28/2018HSBCReiterated RatingSellLow
11/19/2018UBS GroupReiterated RatingHoldLow
11/19/2018BMO Capital MarketsReiterated RatingPositive ➝ Outperform$48.00Medium
11/19/2018InvestecDowngradeBuy ➝ HoldMedium
11/16/2018The Goldman Sachs GroupReiterated RatingSellLow
11/12/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
11/12/2018HSBCReiterated RatingSellMedium
10/23/2018Wolfe ResearchInitiated CoverageOutperformLow
10/8/2018GuggenheimInitiated CoverageBuy ➝ BuyLow
8/16/2018Jefferies Financial GroupDowngradeBuy ➝ HoldMedium
6/12/2018MorningstarReiterated RatingHoldLow
5/25/2018BMO Capital MarketsReiterated RatingBuy$41.00Low
3/22/2018BMO Capital MarketsSet Price TargetBuy$40.00Low
3/19/2018Jefferies Financial GroupUpgradeHold ➝ Buy$28.43 ➝ $36.70Low
2/20/2018BMO Capital MarketsSet Price TargetBuy$40.00Low
2/6/2018SVB LeerinkBoost Price TargetMarket Perform ➝ Market Perform$36.00 ➝ $38.00Medium
2/5/2018Sanford C. BernsteinBoost Price TargetOutperform$40.00 ➝ $42.00High
2/4/2018BMO Capital MarketsReiterated RatingBuyHigh
1/26/2018BMO Capital MarketsReiterated RatingBuy$38.00Low
1/18/2018SVB LeerinkReiterated RatingMkt Perform ➝ Market Perform$33.00 ➝ $36.00Low
1/10/2018BMO Capital MarketsSet Price TargetBuy$38.00Low
12/29/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightLow
11/15/2017BMO Capital MarketsSet Price TargetBuy$38.00N/A
11/7/2017BMO Capital MarketsReiterated RatingBuy$38.00N/A
10/31/2017BMO Capital MarketsSet Price TargetBuy$38.00N/A
10/23/2017SVB LeerinkBoost Price TargetMarket Perform$31.00 ➝ $34.00N/A
10/18/2017CitigroupUpgradeBuyN/A
10/17/2017CowenReiterated RatingHold$37.00N/A
10/16/2017Credit Suisse GroupUpgradeNeutral ➝ OutperformN/A
9/25/2017BNP ParibasUpgradeNeutral ➝ OutperformMedium
9/22/2017Sanford C. BernsteinReiterated RatingMkt Perform ➝ BuyLow
9/22/2017Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$30.00 ➝ $39.00Medium
9/14/2017Liberum CapitalDowngradeBuy ➝ HoldLow
9/6/2017BMO Capital MarketsInitiated CoverageOutperform$38.00High
9/6/2017NatixisUpgradeNeutral ➝ BuyLow
9/1/2017ArgusReiterated RatingBuy$35.00Low
8/9/2017InvestecUpgradeHold ➝ BuyLow
8/9/2017Piper Jaffray CompaniesReiterated RatingBuyLow
8/1/2017Pareto SecuritiesUpgradeSell ➝ HoldLow
7/28/2017Morgan StanleyDowngradeOverweight ➝ Equal WeightHigh
7/28/2017CowenReiterated RatingHold$34.00High
7/27/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$36.00 ➝ $31.00High
7/13/2017The Goldman Sachs GroupReiterated RatingSellHigh
7/13/2017BarclaysReiterated RatingOverweightHigh
7/3/2017BarclaysReiterated RatingOverweightLow
5/17/2017SVB LeerinkReiterated RatingOutperform$33.00 ➝ $36.00Low
5/12/2017Credit Suisse GroupUpgradeUnderperform ➝ NeutralHigh
4/10/2017Jefferies Financial GroupReiterated RatingBuy ➝ HoldLow
4/5/2017UBS GroupDowngradeBuy ➝ Neutral$35.44 ➝ $25.55N/A
3/20/2017SVB LeerinkReiterated RatingOutperformLow
3/9/2017Liberum CapitalInitiated CoverageBuy ➝ BuyLow
3/7/2017BarclaysInitiated CoverageOverweightN/A
3/6/2017CowenReiterated RatingMarket PerformN/A
2/21/2017Berenberg BankReiterated RatingBuyN/A
1/21/2017SVB LeerinkReiterated RatingOutperformN/A
12/13/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
12/9/2016SVB LeerinkUpgradeMarket Perform ➝ Outperform$34.00N/A
11/25/2016Liberum CapitalUpgradeHold ➝ BuyN/A
11/11/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
11/11/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
11/11/2016Beaufort SecuritiesReiterated RatingHoldN/A
11/10/2016SVB LeerinkReiterated RatingMarket PerformN/A
11/10/2016Cantor FitzgeraldReiterated RatingBuyN/A
11/10/2016Bank of AmericaReiterated RatingBuy$41.37N/A
11/10/2016Shore CapitalReiterated RatingHoldN/A
11/7/2016CitigroupReiterated RatingBuyN/A
11/2/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
10/28/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
10/28/2016Cantor FitzgeraldReiterated RatingBuyN/A
10/10/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
10/9/2016SVB LeerinkReiterated RatingHold$35.00N/A
10/8/2016Shore CapitalReiterated RatingHoldN/A
10/5/2016The Goldman Sachs GroupReiterated RatingSellN/A
10/4/2016Bank of AmericaSet Price TargetBuy$41.00N/A
10/4/2016Cantor FitzgeraldReiterated RatingBuyN/A
9/28/2016Shore CapitalReiterated RatingHoldN/A
9/28/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
9/23/2016CitigroupReiterated RatingBuyN/A
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightN/A
9/13/2016BNP ParibasDowngradeOutperform ➝ NeutralN/A
9/12/2016Jefferies Financial GroupUpgradeHold ➝ BuyN/A
9/11/2016Berenberg BankReiterated RatingBuyN/A
9/8/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
9/8/2016Bank of AmericaSet Price TargetBuy$41.40N/A
9/3/2016Shore CapitalReiterated RatingHoldN/A
8/29/2016ArgusUpgradeHold ➝ Buy$38.00N/A
8/26/2016Beaufort SecuritiesReiterated RatingHoldN/A
8/11/2016Beaufort SecuritiesReiterated RatingHoldN/A
8/10/2016Shore CapitalReiterated RatingHoldN/A
8/10/2016CitigroupReiterated RatingBuyN/A
8/8/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
8/8/2016Cantor FitzgeraldReiterated RatingBuyN/A
7/31/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
7/28/2016Cantor FitzgeraldReiterated RatingBuyN/A
7/27/2016Shore CapitalReiterated RatingHoldN/A
7/27/2016CitigroupReiterated RatingBuyN/A
(Data available from 7/25/2016 forward)
AstraZeneca logo
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $58.23
Low: $58.02
High: $58.72

50 Day Range

MA: $58.11
Low: $55.88
High: $60.79

52 Week Range

Now: $58.23
Low: $46.48
High: $60.93

Volume

14,129,812 shs

Average Volume

16,677,040 shs

Market Capitalization

$152.83 billion

P/E Ratio

38.31

Dividend Yield

3.21%

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of AstraZeneca?

The following equities research analysts have issued reports on AstraZeneca in the last year: AlphaValue, Argus, Barclays PLC, Berenberg Bank, Citigroup Inc., Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, Jefferies Financial Group Inc., Morgan Stanley, Oddo Bhf, Piper Sandler, Societe Generale, SVB Leerink LLC, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for AZN.

What is the current price target for AstraZeneca?

2 Wall Street analysts have set twelve-month price targets for AstraZeneca in the last year. Their average twelve-month price target is $119.00, suggesting a possible upside of 104.4%. Piper Sandler has the highest price target set, predicting AZN will reach $175.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $63.00 for AstraZeneca in the next year.
View the latest price targets for AZN.

What is the current consensus analyst rating for AstraZeneca?

AstraZeneca currently has 1 sell rating, 2 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AZN will outperform the market and that investors should add to their positions of AstraZeneca.
View the latest ratings for AZN.

What other companies compete with AstraZeneca?

How do I contact AstraZeneca's investor relations team?

AstraZeneca's physical mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company's listed phone number is 44 20 3749 5000 and its investor relations email address is [email protected] The official website for AstraZeneca is www.astrazeneca.com.